乳腺浸润性导管癌HER2基因和雌孕激素受体过度表达的临床意义

目的探讨乳腺浸润性导管癌HER2基因蛋白过度表达的意义.方法采用HE染色,光镜下观察100例术前未经放、化疗的原发性乳腺浸润性导管癌,并用免疫组织化学技术检测其中HER2 、雌激素受体、孕激素受体蛋白表达情况.结果乳腺浸润性导管癌组织HER2蛋白表达的总阳性率为67%（67/100）;HER2与肿瘤大小呈正相关（P＜0.05）;与淋巴结转移之间有显著性相关（P＜0.05）;按TNM分期可见,1、2、3期乳腺癌中HER2表达阳性率分别为48.57%（17/35）、70.73%（29/41）和87.50%（21/24）,随着肿瘤的进展,HER2表达逐渐增强（P＜0.05）.雌激素受体、孕激素受体蛋白表达阳性率分别为59%（59/100）和47%（47/100）,它们均与临床分期呈负相关（P＜0.05）,与肿瘤大小之间差异无统计学意义（P＞0.05）; 雌激素受体与孕激素受体之间有显著性相关（P＜0.001）;HER2与雌激素受体之间有显著性相关（P＜0.05）.结论 HER2过度表达常发生于乳腺癌,与雌激素受体有关联作用,在乳腺浸润性导管癌发生发展中发挥重要作用.

Clinical Significance of HER2 Oncogene Overexpression in Infilitrating Ductal Breast Cancer

Objective To investigate the significance of HER2 oncogene overexpression in infilitrating ductal breast carcinoma.Methods One hundred cases of infilitrating ductal breast cancer preoperatively without actinotheraphy and chemotherapy were observed under light microscope by HE staining technique and examined the expressions of HER2,estrogen receptor(ER) and progesterone receptor(PR) by immunohistochemical technique.Results The positive rate of HER2 protein expression in breast carcinoma was 67%(67/100).It was positively correlated to the size of tumor and the lymphatic metastasis(P<0.05).According to TNM stages,the positive rates of HER2 protein expression in 1,2,3 stages were 48.57%(17/35), 70.73%(29/41) and(87.50%)(21/24),respectively.It was positively correlated to the clinical stage(P<0.05).The positive rate of ER and PR protein expression in breast carcinoma was 59%(59/100)and 47%(47/100),respectively,and they were negatively related to the clinical stage(P<0.05),but not related to the tumor size(P>0.05).The expression of ER was significantly correlated to the expression of PR(P<0.001).The expression of HER2 was correlated to the expression of ER(P<0.05).Conclusion [WT5B1]HER2 oncogene protein overexpression is usually occurred in breast carcinoma and has correlationship to estrogen receptor.It plays an important role in the development of infilitrating ductal breast cancer.